MARKET

VSTM

VSTM

Verastem
NASDAQ
5.72
0.00
0.00%
After Hours: 5.80 +0.08 +1.40% 18:35 02/27 EST
OPEN
5.63
PREV CLOSE
5.72
HIGH
5.77
LOW
5.61
VOLUME
851.97K
TURNOVER
--
52 WEEK HIGH
11.25
52 WEEK LOW
4.010
MARKET CAP
430.83M
P/E (TTM)
-1.4217
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VSTM last week (0216-0220)?
Weekly Report · 4d ago
Press Release: Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Dow Jones · 02/18 12:31
Verastem Inc. Schedules Conference Call on Q4 and Full-Year Financial Results
Reuters · 02/18 12:30
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Barchart · 02/18 06:30
Weekly Report: what happened at VSTM last week (0209-0213)?
Weekly Report · 02/16 09:45
Weekly Report: what happened at VSTM last week (0202-0206)?
Weekly Report · 02/09 09:46
Analysts Offer Insights on Healthcare Companies: Medical Facilities (OtherMFCSF), Bio-Techne (TECH) and Verastem (VSTM)
TipRanks · 02/06 12:50
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Establishment Labs Holdings (ESTA) and Boston Scientific (BSX)
TipRanks · 02/05 12:21
More
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.

Webull offers Verastem Inc stock information, including NASDAQ: VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.